Co-Ripyso Paed 75/50/150 mg Dispersible tablet
PDF Leaflet Revision Date: 02 July 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of pulmonary tuberculosis in children.
Dosage (summary)
5 days/week; 15 mg/kg Rifampicin, 10 mg/kg Isoniazid, 35 mg/kg Pyrazinamide.
Special Populations
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Safety not established; crosses placenta and excreted in breastmilk.
Key Drug Interactions
- Nevirapine
- Saquinavir
- Ritonavir
- Alcohol
Contraindications
- Hypersensitivity to components
- Jaundice
- Moderate to severe renal impairment
- Diabetes mellitus
- Chronic alcoholism
Common side effects
- Nausea
- Vomiting
- Hepatitis
- Peripheral neuropathy
Counselling Points
- Take on an empty stomach
- May cause urine discoloration
- Avoid alcohol and certain foods
Serious warnings
- Hepatotoxicity
- Monitor liver function
- Risk of severe hepatitis
Important Disclaimer
The Co-Ripyso Paed 75/50/150 mg Dispersible tablet professional information leaflet below is the property of Macleods Pharmaceuticals Sa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
